We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How COO Is Riding Myopia and Fertility Trends Amid Execution Risks
Read MoreHide Full Article
Key Takeaways
COO is tied to premium vision care and fertility demand through CooperVision and CooperSurgical.
MyDay delivered double-digit fiscal Q2 growth, while MiSight revenue rose 24% to $32M.
Asia-Pacific softness, hydrogel exits, cost pressure and litigation payouts still weigh on COO.
The Cooper Companies, Inc. (COO - Free Report) sits at the intersection of two durable healthcare trends: premium vision care and fertility demand. Its CooperVision business benefits from contact lens upgrades, while CooperSurgical gives it exposure to IVF and women’s health.
The issue is execution. Long-term demand remains attractive, but Asia-Pacific softness, portfolio transitions, cost pressure and litigation payouts are still shaping the near-term investment case.
Why Cooper Fits Premium Lens Trends
CooperVision is aligned with the shift toward daily disposable silicone hydrogel lenses, a premium category that supports better mix and recurring demand. In the fiscal second quarter, daily silicone hydrogel lenses grew 8%, with MyDay delivering double-digit growth.
The company is also positioned in torics and multifocals, where revenue rose 7% organically to $364.9 million. MyDay Energys and multifocal products remain important as Cooper expands into new markets and upgrades wearers from legacy hydrogel products.
Alcon (ALC - Free Report) is a relevant peer because it also competes in premium contact lens categories. Johnson & Johnson (JNJ - Free Report) , through Acuvue, adds further competitive intensity across eye-care practitioner channels.
How MiSight Taps a Secular Need
Childhood myopia is one of CooperVision’s clearest long-duration growth themes. MiSight gives Cooper a differentiated position in pediatric myopia control, combining recurring lens use with a clinical need that extends beyond routine vision correction.
MiSight revenue grew 24% to $32 million in the fiscal second quarter. Momentum was supported by Japan, the MyDay MiSight launch in Europe, practitioner education and consumer-awareness campaigns around the back-to-school period.
Why Fertility Keeps Cooper Diversified
CooperSurgical broadens COO beyond vision care through fertility and women’s health. The business benefits from delayed childbirth, improving IVF cycles, expanding access to care and clinic investment in technology and workflow tools.
Fertility revenues rose 10% organically to $143.8 million in the fiscal second quarter. Growth came from genomics, capital equipment and consumables, giving Cooper exposure to recurring demand as well as clinic expansion spending.
Where Trend Exposure Meets Friction
Good industry exposure has not eliminated regional pressure. Asia-Pacific revenue declined 6% organically in the fiscal second quarter, reflecting softness in Japan and China, economic pressure in Korea and the continued rationalization of legacy hydrogel products.
The private-label transition can also create timing noise, while hydrogel exits may weigh into 2027. Larger rivals in contact lenses keep competitive intensity high, especially as practitioners and retailers evaluate premium lens alternatives.
Can COO Convert Trends Into Cash
Cooper’s cash-flow profile remains a support. Management raised its fiscal 2026 free cash flow outlook to roughly $650 million, excluding litigation payouts, and reaffirmed its objective of more than $2.2 billion in free cash flow from fiscal 2026 through fiscal 2028.
5-Yr Free Cash Flow vs Price Chart
Image Source: Zacks Investment Research
Still, conversion is not clean. Tariffs, freight, foreign exchange, lower production at CooperVision and litigation payouts can blunt the near-term earnings benefit from attractive product trends.
How COO’s Rating Signals Frame the Trend Story
The bottom line is balanced. COO has credible exposure to premium lenses, myopia control and fertility, but its Zacks Rank #3 (Hold) fits a story where execution, regional recovery and margin discipline still matter as much as the long-term healthcare themes. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The stock’s Style Scores are more constructive, with a VGM Score of B, Value Score of B and Growth Score of B. These scores suggest a reasonable mix of valuation and growth characteristics. However, the Momentum Score of D points to weaker timing support, reinforcing the need for investors to watch Asia-Pacific trends, cash conversion and cost pressures before taking a more aggressive view.
View the Zacks #1 Rank List
Image: Bigstock
How COO Is Riding Myopia and Fertility Trends Amid Execution Risks
Key Takeaways
The Cooper Companies, Inc. (COO - Free Report) sits at the intersection of two durable healthcare trends: premium vision care and fertility demand. Its CooperVision business benefits from contact lens upgrades, while CooperSurgical gives it exposure to IVF and women’s health.
The issue is execution. Long-term demand remains attractive, but Asia-Pacific softness, portfolio transitions, cost pressure and litigation payouts are still shaping the near-term investment case.
Why Cooper Fits Premium Lens Trends
CooperVision is aligned with the shift toward daily disposable silicone hydrogel lenses, a premium category that supports better mix and recurring demand. In the fiscal second quarter, daily silicone hydrogel lenses grew 8%, with MyDay delivering double-digit growth.
The company is also positioned in torics and multifocals, where revenue rose 7% organically to $364.9 million. MyDay Energys and multifocal products remain important as Cooper expands into new markets and upgrades wearers from legacy hydrogel products.
The Cooper Companies, Inc. PEG Ratio (TTM)
The Cooper Companies, Inc. peg-ratio-ttm | The Cooper Companies, Inc. Quote
Alcon (ALC - Free Report) is a relevant peer because it also competes in premium contact lens categories. Johnson & Johnson (JNJ - Free Report) , through Acuvue, adds further competitive intensity across eye-care practitioner channels.
How MiSight Taps a Secular Need
Childhood myopia is one of CooperVision’s clearest long-duration growth themes. MiSight gives Cooper a differentiated position in pediatric myopia control, combining recurring lens use with a clinical need that extends beyond routine vision correction.
MiSight revenue grew 24% to $32 million in the fiscal second quarter. Momentum was supported by Japan, the MyDay MiSight launch in Europe, practitioner education and consumer-awareness campaigns around the back-to-school period.
Why Fertility Keeps Cooper Diversified
CooperSurgical broadens COO beyond vision care through fertility and women’s health. The business benefits from delayed childbirth, improving IVF cycles, expanding access to care and clinic investment in technology and workflow tools.
Fertility revenues rose 10% organically to $143.8 million in the fiscal second quarter. Growth came from genomics, capital equipment and consumables, giving Cooper exposure to recurring demand as well as clinic expansion spending.
Where Trend Exposure Meets Friction
Good industry exposure has not eliminated regional pressure. Asia-Pacific revenue declined 6% organically in the fiscal second quarter, reflecting softness in Japan and China, economic pressure in Korea and the continued rationalization of legacy hydrogel products.
The private-label transition can also create timing noise, while hydrogel exits may weigh into 2027. Larger rivals in contact lenses keep competitive intensity high, especially as practitioners and retailers evaluate premium lens alternatives.
Can COO Convert Trends Into Cash
Cooper’s cash-flow profile remains a support. Management raised its fiscal 2026 free cash flow outlook to roughly $650 million, excluding litigation payouts, and reaffirmed its objective of more than $2.2 billion in free cash flow from fiscal 2026 through fiscal 2028.
5-Yr Free Cash Flow vs Price Chart
Image Source: Zacks Investment Research
Still, conversion is not clean. Tariffs, freight, foreign exchange, lower production at CooperVision and litigation payouts can blunt the near-term earnings benefit from attractive product trends.
How COO’s Rating Signals Frame the Trend Story
The bottom line is balanced. COO has credible exposure to premium lenses, myopia control and fertility, but its Zacks Rank #3 (Hold) fits a story where execution, regional recovery and margin discipline still matter as much as the long-term healthcare themes. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The stock’s Style Scores are more constructive, with a VGM Score of B, Value Score of B and Growth Score of B. These scores suggest a reasonable mix of valuation and growth characteristics. However, the Momentum Score of D points to weaker timing support, reinforcing the need for investors to watch Asia-Pacific trends, cash conversion and cost pressures before taking a more aggressive view.